New drug and lenvatinib for advanced liver cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug (WGI-0301) combined with an existing liver cancer medicine (lenvatinib). It aims to see if the combination can help people with advanced liver cancer when other treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of liver cancer (HCC) that is advanced or not suitable for surgery.
- You need to have had at least one previous treatment for your cancer that stopped working or caused bad side effects.
- Your liver function must be good enough (Child-Pugh class A or B with a score of 7 or less).
- You must be able to do daily activities with some help (ECOG score 0 or 1).
- You must not have certain serious heart, bleeding, or stomach problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, WGI-0301, for people with advanced hepatocellular carcinoma (HCC, a type of liver cancer) that has progressed after standard treatments. It aims to see if WGI-0301 can help control the cancer when other options have stopped working or caused side effects.
This trial tests a new combination treatment before surgery for liver cancer. It aims to shrink tumors and reduce the chance of cancer coming back after surgery.
This trial tests a new drug called BL-B01D1, alone or together with other drugs, in people with advanced liver cancer that has not improved with other treatments. The goal is to see if these combinations can help shrink tumors or slow the cancer's growth.
This study tests a new treatment (BGB-B2033) for advanced liver cancer that has returned or not responded to previous immune therapy. It compares this new drug to the standard options sorafenib or lenvatinib, which are targeted pills. The goal is to see if BGB-B2033 can help shrink or slow the cancer better than the current treatments.
This trial tests adding lenvatinib (a targeted therapy pill) to a combination of two immunotherapy drugs (durvalumab and tremelimumab) for people with liver cancer that cannot be removed by surgery. The goal is to see if the three-drug approach works better than the two immunotherapy drugs alone.
This trial tests a combination of two or three drugs for advanced liver cancer that cannot be removed with surgery. The goal is to see if adding a third drug (gefitinib) to the standard two-drug combination helps patients live longer with better quality of life.
Hear when a new Advanced Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.